BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 22980449)

  • 1. Prescription opioid abuse, chronic pain, and primary care: a Co-occurring Disorders Clinic in the chronic disease model.
    Pade PA; Cardon KE; Hoffman RM; Geppert CM
    J Subst Abuse Treat; 2012 Dec; 43(4):446-50. PubMed ID: 22980449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose transdermal buprenorphine - long-term use and co-medication with other potentially addictive drugs.
    Nordbø A; Skurtveit S; Borchgrevink PC; Kaasa S; Fredheim OM
    Acta Anaesthesiol Scand; 2012 Jan; 56(1):88-94. PubMed ID: 22092357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Less pain, more gain: buprenorphine-naloxone and patient retention in treatment.
    Renzelli CM; Capretto NA
    J Addict Dis; 2006; 25(3):97-104. PubMed ID: 16956874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute pain control challenges with buprenorphine/naloxone therapy in a patient with compartment syndrome secondary to McArdle's disease: a case report and review.
    McCormick Z; Chu SK; Chang-Chien GC; Joseph P
    Pain Med; 2013 Aug; 14(8):1187-91. PubMed ID: 23647815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
    Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
    J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urine Spiking in a Pain Medicine Clinic: An Attempt to Simulate Adherence.
    Lee D; Bazydlo LA; Reisfield GM; Goldberger BA
    Pain Med; 2015 Jul; 16(7):1449-51. PubMed ID: 25522892
    [No Abstract]   [Full Text] [Related]  

  • 9. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In brief: Buprenorphine/naloxone (Zubsolv) for opioid dependence.
    Med Lett Drugs Ther; 2013 Oct; 55(1427):83. PubMed ID: 24129113
    [No Abstract]   [Full Text] [Related]  

  • 11. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.
    Roux P; Sullivan MA; Cohen J; Fugon L; Jones JD; Vosburg SK; Cooper ZD; Manubay JM; Mogali S; Comer SD
    Pain; 2013 Aug; 154(8):1442-8. PubMed ID: 23707283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine for postoperative pain following general surgery in a buprenorphine-maintained patient.
    Book SW; Myrick H; Malcolm R; Strain EC
    Am J Psychiatry; 2007 Jun; 164(6):979. PubMed ID: 17541066
    [No Abstract]   [Full Text] [Related]  

  • 13. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.
    Mintzer IL; Eisenberg M; Terra M; MacVane C; Himmelstein DU; Woolhandler S
    Ann Fam Med; 2007; 5(2):146-50. PubMed ID: 17389539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine/Naloxone dose and pain intensity among individuals initiating treatment for opioid use disorder.
    Becker WC; Ganoczy D; Fiellin DA; Bohnert AS
    J Subst Abuse Treat; 2015 Jan; 48(1):128-31. PubMed ID: 25312475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.
    Nielsen S; Hillhouse M; Weiss RD; Mooney L; Sharpe Potter J; Lee J; Gourevitch MN; Ling W
    Am J Addict; 2014; 23(4):343-8. PubMed ID: 24112096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction.
    Neumann AM; Blondell RD; Jaanimägi U; Giambrone AK; Homish GG; Lozano JR; Kowalik U; Azadfard M
    J Addict Dis; 2013; 32(1):68-78. PubMed ID: 23480249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pain volatility and prescription opioid addiction treatment outcomes in patients with chronic pain.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Exp Clin Psychopharmacol; 2015 Dec; 23(6):428-35. PubMed ID: 26302337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diverse clinical uses of opioid receptor drugs.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 May; 48(5):11-4. PubMed ID: 20415289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychiatric and medical comorbidities, associated pain, and health care utilization of patients prescribed buprenorphine.
    Mark TL; Dilonardo J; Vandivort R; Miller K
    J Subst Abuse Treat; 2013; 44(5):481-7. PubMed ID: 23265445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of opioid painkiller dependence in primary care: ongoing recovery with buprenorphine/naloxone.
    Hard B
    BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25432908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.